Sub-retinal Transplantation of hESC Derived RPE(MA09-hRPE)Cells in Patients With Stargardt's Macular Dystrophy

Inclusion Criteria: * Adult male or female over 18 years of age. * Clinical diagnosis of advanced SMD. * If known, the patient's genotype will be recorded in the medical history, if unknown, patient will allow for the submission of a sample for genotyping.Clinical findings consistent with SMD. * The visual acuity of the eye to receive the transplant will be no better than 20/400. The visual acuity of the eye in the better vision cohort to receive the transplant will be no better than 20/100. * The visual acuity of the eye that is not to receive the transplant will be no better than 20/400 for the worse vision patients and no worse than 20/100 for the better vision patients. * Peripheral visual field constriction documented on standard kinetic visual field testing. * Electrophysiological findings consistent with SMD. * Medically suitable to undergo vitrectomy and subretinal injection. * Medically suitable for general anesthesia or waking sedation, if needed. * Medically suitable for transplantation of an embryonic stem cell line: * Normal serum chemistry (sequential multi-channel analyzer 20 \[SMA- 20\]) and hematology (complete blood count \[CBC\], prothrombin time \[PT\], and activated partial thromboplastin time \[aPTT\]) screening tests. * Negative urine screen for drugs of abuse. * Negative human immunodeficiency virus (HIV), hepatitis B (HBV), hepatitis C (HCV) serologies. * No history of malignancy,with the exception of successfully treated basal cell or squamous cell …